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Abstract
TNF-related apoptosis-inducing ligand (TRAIL; Apo2) has been shown to promote intestinal cell differentiation. Nuclear
factor of activated T cells (NFAT) participates in the regulation of a variety of cellular processes, including differentiation.
Here, we examined the role of NFAT in the regulation of TRAIL in human intestinal cells. Treatment with a combination of
phorbol 12-myristate 13-acetate (PMA) plus the calcium ionophore A23187 (Io) increased NFAT activation and TRAIL
expression; pretreatment with the calcineurin inhibitor cyclosporine A (CsA), an antagonist of NFAT signaling, diminished
NFAT activation and TRAIL induction. In addition, knockdown of NFATc1, NFATc2, NFATc3, and NFATc4 blocked PMA/Io
increased TRAIL protein expression. Expression of NFATc1 activated TRAIL promoter activity and increased TRAIL mRNA and
protein expression. Deletion of NFAT binding sites from the TRAIL promoter did not significantly abrogate NFATc1-
increased TRAIL promoter activity, suggesting an indirect regulation of TRAIL expression by NFAT activation. Knockdown of
NFATc1 increased Sp1 transcription factor binding to the TRAIL promoter and, importantly, inhibition of Sp1, by chemical
inhibition or RNA interference, increased TRAIL expression. These studies identify a novel mechanism for TRAIL regulation
by which activation of NFATc1 increases TRAIL expression through negative regulation of Sp1 binding to the TRAIL
promoter.
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Introduction
The mammalian intestinal mucosa undergoes a process of
continual renewal, characterized by active proliferation of stem
cells localized near the base of the crypts, progression of these cells
up the crypt-villus axis with cessation of proliferation and
subsequent differentiation into one of the four primary cell types
[1]. In the process of differentiation, enterocytes acquire structural
features of mature cells, such as microvilli, and express specific
gene products such as brush border enzymes [2]. The differen-
tiated enterocytes, which make up the majority of the cells of the
gut mucosa, then undergo a process of programmed cell death
(i.e., apoptosis) and are extruded into the gut lumen [3]. The
cellular mechanisms regulating this tightly regimented process
have not been clearly defined.
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL; also called Apo-2 ligand), a novel member of the TNF
family, was identified based on homology to the extracellular
domains of TNF and FasL (CD95L) [4,5]. Unlike TNF and FasL,
TRAIL is expressed in a variety of cell types and is capable of
inducing apoptosis in neoplastic cells [6]. In addition, TRAIL
blockade results in hyperproliferation of synovial cells and
lymphocytes, whereas TRAIL inhibits DNA synthesis in lympho-
cytes by blocking cell cycle progression [7]. Recently, TRAIL has
been shown to promote dendritic cell differentiation [8]. We have
found that inhibition of phosphatidylinositol 3-kinase (PI3-kinase)
or overexpression of PTEN enhances intestinal cell differentiation
[9] and increases TRAIL expression in intestinal cells [10].
Moreover, TRAIL is expressed in the differentiated region of the
small bowel and colonic mucosa. Exposure of the fetal human
intestine cell line, tsFHI, to recombinant TRAIL increased the
expression levels of the canonical differentiation marker dipepti-
dylpeptidase IV (DPPIV) and the cyclin-dependent kinase
inhibitors p21Waf1 and p27Kip1 [11], which mediate the induction
of growth arrest and the stabilization of differentiated traits,
respectively. Together, these studies demonstrate an important
role for TRAIL in the regulation of intestinal cell differentiation.
The nuclear factor of activated T cells (NFATc) proteins are a
family of transcription factors whose activation is controlled by
calcineurin, a calcium-dependent phosphatase. Four distinct genes
encoding closely related NFATc proteins (NFATc1–4) [12] have
been identified and are involved in multiple biological processes
ranging from lymphocyte activation and development to cardiac
hypertrophy [13]. NFAT, which exists in a highly phosphorylated
form in the cytoplasm, translocates into the nucleus upon
dephosphorylation by the phosphatase calcineurin in response to
increases in intracellular calcium, where it binds to enhancer
elements of specific genes leading to transcriptional activation
[14]. Calcineurin activity can be blocked by cyclosporin A (CsA),
thereby preventing the nuclear translocation of NFAT. NFAT
plays a critical role in the regulation of T cell receptor-mediated
CD95 ligand expression [15] and has been shown to regulate cell
differentiation and development in a number of cell types. For
example, NFAT regulates the development of the cardiovascular
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system [16]. Primary keratinocyte cell differentiation is associated
with nuclear localization of NFAT; this effect is blocked by CsA
[17]. NFAT also plays a role in adipocyte differentiation [18] and
stimulation of myogenic differentiation via activation of calci-
neurin [19]. Recently, we have shown that activation of NFAT
increases PTEN and p27kip1 expression and decreases Akt
phosphorylation and that NFAT activation is required for sodium
butyrate mediated-intestinal cell differentiation [20]. However, the
NFAT target genes, which may contribute to intestinal differen-
tiation, are not known.
Previously, we cloned the human TRAIL promoter and
identified a number of putative transcription factor binding sites
including NFAT and Sp1 sequences [21]. Given the important
role of NFAT in tissue differentiation and the fact that NFAT
binding sites are located in the TRAIL promoter, we determined
whether NFAT plays a role in TRAIL regulation. Here, we show
induction of TRAIL expression in intestinal-derived cells by
activation of the NFAT pathway. Inhibition of NFAT decreased
TRAIL protein expression while overexpression of NFATc1
increased TRAIL promoter activity and increased TRAIL protein
and mRNA expression. Deletion of putative NFAT binding sites in
the TRAIL promoter did not affect NFATc1 induction of TRAIL
promoter activity. Knockdown of NFATc1 increased Sp1
transcription factor binding and, importantly, inhibition or
knockdown of Sp1 increased TRAIL expression. These findings
demonstrate that activation of NFAT increases TRAIL expression
through negative regulation of Sp1 binding to the TRAIL
promoter in human intestinal cells.
Results
NFAT activation increases TRAIL expression in HT29 cells
Previously, we have shown that inhibition of PI3-kinase, which
augments enterocyte-like differentiation of HT29 and Caco-2
human colon cancer cells [9], increased TRAIL expression [10].
The importance of TRAIL in intestinal cell differentiation has
subsequently been demonstrated [11]. In our current study, we
have investigated the cellular mechanisms regulating TRAIL
expression in these intestinal-derived cell lines. HT29 cells were
pretreated with CsA, an inhibitor of calcineurin [22], followed by
treatment with PMA (100 nM) plus Io (2.5 mM), pharmacological
agents that activate NFAT in intestinal cell types [23], in the
presence or absence of CsA for 2 h. Whole cell lysates were
analyzed by Western blot using anti-TRAIL antibody (Figure 1A).
PMA/Io treatment resulted in the induction of TRAIL expression
compared with control cells treated with vehicle (i.e., Me2SO); this
induction was attenuated by pretreatment with CsA. To test
whether PMA/Io activates NFAT, we performed EMSAs with
nuclear extracts obtained from HT29 cells treated for 60 min with
PMA/Io using a commercial oligonucleotide with consensus
binding sites for NFAT as the probe. As shown in Figure 1B,
treatment with PMA/Io increased NFAT binding activity. As
expected, the formation of the increased binding complex was
abolished in extracts from cells pretreated with CsA. The
specificity of the complex was determined using unlabeled cold
probe as a competitor. Our results suggest a role for NFAT
activation in TRAIL induction in intestinal cells.
Knockdown of NFAT blocks PMA/Io induced TRAIL
expression
Four classical isoforms of NFAT have been identified [12]. To
determine which of the NFAT isoforms are involved in TRAIL
regulation, EMSAs were performed. As shown in Figure 2A,
treatment with PMA/Io increased NFAT binding activity as noted
by increased density of band b. The specificity of this binding was
confirmed by competition studies using cold wild type and mutant
competitor probes. Addition of anti-NFATc1 antibody to the
mixture abolished bands b and c. Band b was also abolished when
anti-NFATc2 antibody was added to the mixture and a super-
shifted band (band d) was observed. When anti-NFATc4 antibody
was added to the mixture, band a was abolished; there was no
effect on the binding complex with addition of anti-NFATc3
antibody. These results demonstrate that NFATc1, NFATc2, and
NFATc4 isoforms are present in HT29 cells. Treatment with
PMA/Io increased band b, suggesting a role of NFATc1 or
NFATc2 in PMA/Io induction of TRAIL expression in HT29
cells.
To confirm the contribution of each isoform to TRAIL
expression, individual NFAT isoforms were silenced by transfec-
tion of HT29 cells with the relevant siRNA. As shown in Figure 2B,
transfection of NFATc2 or NFATc3 siRNA blocked PMA/Io
increased TRAIL protein expression, while transfection of
NFATc1 or NFATc4 siRNA not only blocked PMA/Io induced
TRAIL expression but also decreased basal TRAIL protein
expression compared with cells transfected with non-targeting
control siRNA. The knockdown of individual NFAT isoforms was
confirmed by RT-PCR as shown in Figure 2C. The results
indicate that, although NFATc1 and NFATc2 are important for
PMA/Io increased TRAIL expression, NFATc3 and NFATc4
may also play a role in TRAIL regulation in human intestinal cells.
Overexpression of NFATc1 increases TRAIL expression in
HT29 and Caco-2 cells
To further determine the role of NFAT in TRAIL regulation,
HT29 cells were transfected with a plasmid encoding NFATc1, or
the control pDF30 vector; TRAIL protein expression was assayed
Figure 1. PMA/Io-mediated induction of TRAIL expression was
attenuated by cyclosporin A, a potent calcineurin inhibitor in
HT29 cells. (A) HT29 cells were pre-treated with cyclosporin A (CsA)
for 30 min followed by the combination of PMA (100 nM) plus Io
(2.5 mM) with CsA for 2 h. Total protein was extracted from cells and
resolved by SDS-PAGE, transferred to a PVDF membrane and probed
with anti-TRAIL and anti-b-actin antibodies. TRAIL signals from three
separate experiments were quantitated densitometrically and ex-
pressed as fold-change with respect to b-actin. (Data shown as mean
6 standard error of the mean; *, P,0.05, PMA/Io or PMA/Io plus CSA vs.
control; +, P,0.05, PMA/Io plus CSA vs. PMA/Io). (B) Cells were treated
with PMA/Io for 60 min in the presence or absence of CsA. Nuclear
protein was extracted and NFAT DNA binding was analyzed by EMSA.
Unlabeled NFAT oligonucleotide was added in molar excess to confirm
binding specificity (competitor).
doi:10.1371/journal.pone.0019882.g001
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by Western blotting. Overexpression of NFATc1 by transfection
with the pSH-NFATc1 vector increased TRAIL protein expres-
sion compared with the control pDF30 vector (Figure 3A).
NFATc1 overexpression was confirmed using anti-NFATc1
antibody. To address whether TRAIL mRNA induction paralleled
the increase in TRAIL protein, RT-PCR (Figure 3B) and real time
PCR (Figure 3C) were performed with total RNA extracted from
transfected HT29 cells; TRAIL mRNA induction was noted with
NFATc1 overexpression.
To determine whether NFAT induction of TRAIL expression
was regulated at the level of promoter activity, Caco-2 human
colon cancer cells were transfected with plasmids encoding
NFATc1, NFATc2, NFATc3, NFATc4 or control vectors
pDF30 or pcDNA3.1 together with a 1371 bp TRAIL proximal
promoter construct [21]. Overexpression of NFATc1 resulted in
an induction of TRAIL promoter activity, whereas NFATc3 and
NFATc4 overexpression only slightly increased TRAIL promoter
activity (Figure 3D). The overexpression of Flag-tagged NFAT
protein expression was confirmed by Western blotting using anti-
Flag antibody (Figure 3E). RT-PCR was performed with total
RNA extracted from NFATc1 transfected Caco-2 cells; similar to
HT29 cells, overexpression of NFATc1 increased TRAIL mRNA
levels in Caco-2 cells (Figure 3F). Taken together, these results
demonstrate both TRAIL mRNA and protein induction by the
NFAT signaling pathway in HT29 and Caco-2 human colon
cancer cells.
Identification and functional assessment of putative
NFAT binding sites
Previously, we have reported two NFAT binding sites
identified in the 1371 bp TRAIL promoter by computer
sequence analysis using MatInspector V2.2 software [21] as
shown in Figure 4A (N1 and N2). In addition, we also found three
other potential NFAT binding sites, N3, N4, and N5, by
computer sequence analysis using Genomatrix software. All of
these five sites were located in the 2923 to 2383 region of the
TRAIL promoter.
To determine whether PMA/Io treatment affects the binding
activity of these potential NFAT binding sites, EMSA was
performed. Treatment with PMA/Io increased N4 and N5, but
Figure 2. Knockdown of NFAT blocked PMA/Io-induced TRAIL expression in HT29 cells. (A) HT29 cells were treated with PMA/Io for
60 min and NFAT DNA binding activity was assessed by EMSA using nuclear extracts. In addition, nuclear extracts were incubated with 32P-labeled
NFAT specific DNA probe alone or in the presence of unlabeled wild type (cold) NFAT oligonucleotide or mutant NFAT oligonucleotide or specific
antibodies to either NFATc1, NFATc2, NFATc3, or NFATc4. (B) HT29 cells were transfected with NFATc1, c2, c3, c4 or control siRNA. After a 48 h
incubation, transfected cells were treated with PMA/Io for 2 h. Total protein was extracted and TRAIL expression levels were determined by Western
blotting using anti-TRAIL antibody. The membrane was stripped and reprobed using anti-b-actin antibody to confirm equal loading. TRAIL signals
from three separate experiments were quantitated densitometrically and expressed as fold-change with respect to b-actin. (Data shown as mean 6
standard error of the mean; *, P,0.05, PMA/Io plus control siRNA vs. control siRNA; +, P,0.05, PMA/Io plus NFATC1 siRNA or NFATC4 siRNA vs. PMA/Io
plus control siRNA). (C) To confirm NFAT suppression, total RNA was extracted from cells and NFAT expression was assessed by RT-PCR.
doi:10.1371/journal.pone.0019882.g002
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not N1, N2, and N3 binding activity (Figure 4B), suggesting N4
and N5 may be important for TRAIL regulation. To demonstrate
whether NFAT directly binds to the putative N4 or N5 NFAT
binding sites, supershift assays were performed. As shown in
Figure 4C, the addition of antibodies against NFATc1, NFATc2,
or NFATc3 resulted in shifted bands (a, b, c, respectively) or
diminished binding of the protein-DNA binding complex. We did
not identify NFATc4 binding to these two sites.
To determine the contribution of these NFAT binding sites to
TRAIL promoter activation, deletional analyses were performed.
Caco-2 cells were transfected with two 59- deletion promoter
constructs together with control vector pDF30 or a plasmid
encoding NFATc1. As shown in Figure 4D, deletion of NFAT
binding sites from 21371 to 2165 did not abrogate NFATc1
induction of the TRAIL promoter activity. Deletion from 21371
to 235 resulted in a marked decrease in basal promoter activity
and eliminated NFATc1 induction. Although NFAT transcription
factors bind to the TRAIL promoter, our results showed that
NFATc1 increased TRAIL promoter activity independent of
direct binding to the promoter. Instead, the region between 2165
and 235 contains elements important for NFATc1 induction of
TRAIL expression.
Figure 3. Overexpression of NFATc1 increased TRAIL expression in HT29 and Caco-2 cells. HT29 cells were transfected with either the
control plasmid (pDF30) or Flag-tagged NFATc1. At 48 h posttransfection, cells were harvested. (A) Expression of TRAIL and NFATc1 protein was
detected by Western blot using anti-TRAIL or anti-Flag antibodies. Membranes were reprobed with anti-b-actin antibody to assess loading. (B and C)
Total RNA was extracted, and RT-PCR (B) or real time PCR (C) performed. (Data shown as mean 6 standard error of the mean. *, P,0.05, vs. control
plasmids). (D) Caco-2 cells were transfected with a proximal 1371 bp TRAIL promoter construct together with either control plasmid pDF30,
pCDNA3.1 or Flag-tagged NFATc1, NFATc2, NFATc3 or NFATc4. At 48 h posttransfection, cells were harvested; luciferase activity was then assayed. All
results were normalized for transfection efficiency using the pRL-Tk-luc plasmid (Promega). (Data shown as mean 6 standard error of the mean. *,
P,0.05, vs. control plasmids). (E) Expression of NFATc1, NFATc2, NFATc3 and NFATc4 in Caco-2 cells was confirmed by Western blot using anti-Flag
antibody. (F) Caco-2 cells were transfected with control plasmid, pDF30, or Flag-tagged NFATc1. At 48 h posttransfection, total RNA was extracted,
and RT-PCR performed using primers to human TRAIL and b-actin. TRAIL signals from three separate experiments were quantitated densitometrically
and expressed as fold-change with respect to b-actin (Data shown as mean 6 standard error of the mean).
doi:10.1371/journal.pone.0019882.g003
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To further identify the NFATc1 responsive elements in the
2165 TRAIL promoter, five oligonucleotide probes were
synthesized. These probes contained all of the putative transcrip-
tional binding sites identified between 2169 and 233 by
computer sequence analysis (Figure 5A). HT29 cells were
transfected with non-targeting control siRNA or siRNA targeting
NFATc1. Forty-eight h after transfection, cells were harvested and
nuclear protein extracted and EMSAs performed. There was no
obvious binding complex found using probes 1, 2 or 4.
Interestingly, knockdown of NFATc1 increased the binding
activities of probes 4 and 5 (Figure 5B).
To further confirm NFATc1 regulation of TRAIL expression,
HT29 cells stably transfected with the shRNA targeting NFATc1
and the control shRNA (CON) were established. Complete
knockdown of NFATc1 in clones 33, 36 and 35 and partial
knockdown of NFATc1 in clone 34 were confirmed in HT29 cells
transfected with NFATc1 shRNA by RT-PCR (Figure 5C). The
increase of probe 4 and probe 5 binding activities by blockade of
NFATc1 was demonstrated by EMSA (Figure 5D). Consistently,
decreased TRAIL protein expression levels were noted in these
stable cell lines transfected with NFATc1 shRNA, compared with
cells transfected with control shRNA detected by Western blotting
(Figure 5E). These results suggested that probes 4 and 5 contain
elements important for NFATc1 induction of TRAIL expression.
NFATc1 regulates TRAIL expression through negative
regulation of Sp1 binding to the TRAIL promoter
Since both probe 4 and probe 5 contain putative Sp1 binding
sites (Figure 5A), we next determined whether Sp1 protein
comprised part of the increased binding complex to probes 4
and 5 associated with NFATc1 knockdown. Nuclear extracts from
HT29 cells transfected with non-targeting control siRNA or
siRNA targeting NFATc1 were isolated and EMSAs performed.
As shown in Figure 6, A and B, the specificity of the complex was
determined using unlabeled oligonucleotide as a competitor. In
addition, when an unlabeled, commercially available Sp1 probe
was added to the mixture, the increased binding complex was
significantly diminished. In contrast, addition of unlabeled NFAT
Figure 4. Deletion of NFAT binding sites did not eliminate NFATc1 increased TRAIL promoter activity. (A) Nucleotide sequences of the
putative NFAT binding sites in the human TRAIL promotor. The 1371 bp TRAIL promoter contains five putative NFAT binding sites (N1, N2, N3, N4,
and N5). The numbers on the left are the nucleotide positions relative to the transcriptional start site. (B) HT29 cells were treated with or without
PMA/Io for 60 min and nuclear protein extracted; EMSA was performed with 32P-labeled probes spanning each of the five NFAT binding sites (N1, N2,
N3, N4, and N5) in the human TRAIL promoter. (C) Specific binding of various NFAT isoforms with probe N4 or N5 was determined by addition of
antibodies to either NFATc1, NFATc2, NFATc3, or NFATc4. Specific binding of NFAT was also confirmed by cold competition using unlabeled wild
type (WT) and mutant probes at 100-fold molar excess. (D) Caco-2 cells were transfected with constructs containing 235 or 2165 TRAIL promoter
sequences together with either control plasmid pDF30, or Flag-tagged NFATc1, respectively. At 48 h posttransfection, cells were harvested; and
luciferase activity was assayed. All results were normalized for transfection efficiency using the pRL-Tk-luc plasmid (Promega). (Data shown as mean 6
standard error of the mean; *, P,0.05, DF30 or NFATc1 plus 2165 bp promoter vs. DF30 or NFATc1 plus 235 promoter, respectively; +, P,0.05, DF30
plus 2165 bp promoter vs. NFATc1 plus 2165 bp promoter).
doi:10.1371/journal.pone.0019882.g004
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Figure 5. Identification of NFATc1 responsive sequences in the TRAIL promoter. (A) Double-stranded oligonucleotides corresponding to
all of the potential transcriptional binding sites in human TRAIL promoter 2169 to 233 were synthesized and used for DNA binding analysis. The
putative Sp1 binding sequences are boxed, which are also overlapped with other transcription factor binding sequences. (B) HT29 cells were treated
with or without PMA/Io for 60 min and nuclear protein extracted. Double-stranded oligonucleotides (as shown in A) were radiolabeled and tested for
DNA binding by EMSA. The arrows indicated the increased binding complexes. (C) Total RNA from HT29 cells stably transfected with control (CON) or
four individual shRNAs targeting human NFATc1 (clones 33, 34, 35, 36) was extracted and RT-PCR performed for NFATc1 mRNA expression. (D and E)
Nuclear protein (D) or total protein (E) from HT29 cells stably transfected with control (CON) or NFATc1 shRNA (clones 33, 34, 36) was extracted. EMSA
was performed (D) using probe 4 and probe 5 (sequences shown in Figure 6). Western blotting was performed for the analysis of TRAIL expression (E);
membranes were stripped and re-probed with anti-b-actin to confirm equal loading. TRAIL signals from two separate experiments were quantitated
densitometrically and expressed as fold-change with respect to b-actin (Data shown as mean 6 standard error of the mean).
doi:10.1371/journal.pone.0019882.g005
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or ETS probes did not alter the binding complex. NFATc1
knockdown did not affect the Sp1 protein expression level (Wang
et al., data not shown); therefore, increased Sp1 binding to the
TRAIL promoter may not be through increased Sp1 protein
expression.
To further confirm these findings, occupancy of the TRAIL
promoter by Sp1 in cells was further analyzed using a ChIP assay.
Cross-linked chromatin was prepared from HT29 cells transfected
with control siRNA or siRNA targeting NFATc1. The human
TRAIL promoter region containing the Sp1 binding sites was
precipitated using either the anti-Sp1 antibody or IgG, and using
the probe 1 (forward) and the probe 5 (reverse) shown in Figure 5A
as gene-specific primers and the sequence (136 bp) encompassing
the Sp1 binding sites was amplified. As shown in Figure 6C, the
binding of the TRAIL promoter and Sp1 was confirmed and
consistent with our EMSA results, knockdown of NFATc1
increased Sp1 binding to TRAIL promoter. These results
demonstrate that knockdown of NFATc1 increased Sp1 protein
binding to the 2165/235 region of the TRAIL promoter.
Since Sp1 protein directly binds to the TRAIL promoter and
knockdown of NFATc1 decreased TRAIL expression and
increased Sp1 binding, we next investigated whether Sp1
transcription factor regulates TRAIL expression. Mithramycin
has affinity for the GGGCGG binding sequence, and effectively
blocks the binding of Sp1 [24]. HT29 cells were treated with
mithramycin for 24 h and total protein extracted; TRAIL
expression was determined by Western blotting. As shown in
Figure 6D, treatment with mithramycin significantly increased
TRAIL expression in HT29 cells. Sp1 binding to the TRAIL
promoter has been demonstrated [25]. To further delineate Sp1
Figure 6. Sp1 mediated NFATc1 regulation of TRAIL expression. HT29 cells were transiently transfected with control siRNA or siRNA
targeting NFATc1. Nuclear protein was extracted and EMSAs performed. Nuclear extracts were incubated with 32P-labeled probe 4 (A) or probe 5 (B)
alone or in the presence of unlabeled wild type (cold) probe 4 or probe 5, the Sp1 oligonucleotide, the NFAT oligonucleotide, or the ETS
oligonucleotide, respectively. (C) HT29 cells were subjected to ChIP assay; soluble chromatin was prepared from HT29 cells transfected with control
siRNA or siRNA targeting NFATc1 and immunoprecipitated with Sp1 antibody or IgG. Total (Input) and immunoprecipitated DNAs were then PCR-
amplified using primer pairs covering the Sp1 binding sites within the human TRAIL promoter. (D) HT29 cells were treated with the Sp1 inhibitor
mithramycin for 24 h and total protein extracted and Western blotting performed using anti-TRAIL antibody. (E) HT29 cells were transiently
transfected with control siRNA or siRNA targeting Sp1. Forty-eight h after transfection, total protein was extracted and Western blotting performed to
assess TRAIL expression (left panel) or to confirm knockdown of Sp1 (right panel). Membranes were stripped and re-probed with anti-b-actin
antibody to confirm equal loading.
doi:10.1371/journal.pone.0019882.g006
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transcription factor regulation of TRAIL expression, HT29 cells
were transfected with non-targeting control siRNA or siRNA
targeting Sp1. Forty-eight h after transfection, cells were harvested
and total protein extracted and Western blotting performed. In
agreement with the Sp1 inhibition, transfection of Sp1 siRNA
(Figure 6E) significantly increased TRAIL protein expression.
Knockdown of Sp1 was confirmed by Western blotting using anti-
Sp1 antibody. Collectively, these results demonstrate that NFATc1
regulated Sp1 protein binding to the TRAIL promoter and thus,
regulated TRAIL expression.
Discussion
Previously, we demonstrated that intestinal cell differentiation is
associated with the induction of TRAIL expression [10].
Subsequently, Rimondi et al. [11] showed that TRAIL promotes
intestinal cell differentiation. Analysis of the TRAIL promoter
identified several putative transcription factor binding sites,
including NFAT, which might be involved in the regulation of
TRAIL expression [21]. Here, we show that activation of the
NFATc1 isoform increased TRAIL expression, not through the
direct binding to the TRAIL promoter, but indirectly through the
regulation of Sp1 binding.
Although five NFAT transcription factor binding sites were
identified in the TRAIL promoter, our results showed that
NFATc1 increased TRAIL promoter activity not by direct binding
but, alternatively, through negative regulation of Sp1 binding to
the promoter. Recently, we have found that knockdown of
NFATc1 decreased PTEN expression and increased the phos-
phorylation levels of Akt while overexpression of NFATc1
increased PTEN expression and decreased Akt phosphorylation
in HT29 and Caco-2 cells [20]. In addition, our previous findings
demonstrated that inhibition of PI3-kinase or overexpression of
PTEN enhanced intestinal cell differentiation [9] and increased
TRAIL expression in intestinal cells [10]. These results suggest
that NFATc1 regulates TRAIL expression through the induction
of PTEN induction. Activation of PI3-kinase increases Sp1
activation in various cell types [26,27,28,29]. We also have found
that overexpression of PTEN inhibits Sp1 reporter activity in
HT29 and Caco-2 cells (unpublished data). Moreover, PTEN
downregulates p75NTR expression by decreasing DNA-binding
activity of Sp1 [30]. PTEN dephosphorylates the Sp1 transcription
factor [31], the phosphorylation status of which directly impacts its
ability to bind to some DNA promoter regions [32,33]. Therefore,
it is reasonable to postulate that activation of NFATc1 increases
PTEN expression and, as a result, decreases Sp1 binding to
TRAIL promoter and increases TRAIL expression. Although
knockdown of NFATc1 increased Sp1 binding to the TRAIL
promoter, knockdown of NFATc1 did not affect Sp1 protein
expression levels, suggesting that the increased Sp1 protein
binding to the TRAIL promoter, associated with NFATc1
knockdown, may not be through increased Sp1 protein expression.
Similar to our findings showing induction of TRAIL by NFAT,
activation of NFAT isoforms, including NFATc1, up-regulated
FasL expression [34,35] and TNFa expression [36] in several cell
types. NFAT has been shown to play a pro-apoptotic role through
the up-regulation of FasL [35,37]. Taken together with our
current findings, these studies demonstrate that the activation of
NFAT results in the induction of apoptotic-related proteins in
various cell types. Recently, activation of NFATc1 was noted
specifically in the mononuclear cells of the inflamed colonic
mucosa from patients with ulcerative colitis [38]. Moreover,
increased expression of TRAIL and FasL has been identified in the
intestinal epithelial cells and colonic lamina propria, respectively,
associated with inflammatory bowel disease (IBD) [39,40]. It is
well known that TNF is one of the most potent effector cytokines
in the pathogenesis of IBD [41]. It is possible that induction of
these TNF family members is due, in part, to the activation of
NFATc1 in the abnormal intestinal cells in patients with IBD.
Given the fact that CsA is currently an effective therapy for
patients with IBD [42], NFAT-dependent induction of TNF
family members may play an important role in the progression of
this disease.
Sp1 recognizes and binds to GC/GT boxes and regulates a
large number of mammalian genes in normal and transformed
cells [43]. Activation of Sp1 not only increases but also represses
expression of certain genes. For example, Sp1 has been shown to
bind to the promoter and repress transcription of the human
telomerase reverse transcriptase [44] and the human b-like globin
gene expression [45]. In addition, Sp1 can repress the expression
of certain genes by recruiting histone deacetylase 1 (HDAC1) to
deacetylate histones [44,46]. Consistent with these findings, our
results show that Sp1 binds to the TRAIL promoter and that
inhibition of Sp1 by mithramycin or siRNA targeting Sp1
significantly increased TRAIL expression, suggesting a negative
regulation of TRAIL expression by Sp1 in human intestinal cells.
It is likely that inhibition or knockdown of Sp1 may diminish the
promoter repression and result in TRAIL induction.
Sp1 binds the Myc-associated zinc finger protein (MAZ)
promoter region and represses promoter activity [47]. It has been
reported that methylation plays an important role in this
suppression of transcription and that the interaction of Sp1 with
DNA methyltransferase (DNMT) contributes to Sp1-mediated
repression. DNMT inhibitors induce TRAIL expression in various
cell types [25,48]. Moreover, inhibition of DNMT restores PTEN
expression by epigenetic mechanisms and results in the inhibition
of the PI3-kinase/Akt pathway [49], an important signaling
pathway that we and others have shown regulates TRAIL
expression [10,48]. Whether DNMT is involved in Sp1 regulation
of TRAIL expression and the cross-talk between Sp1 and PTEN/
PI3-kinase/Akt signaling deserve to be further investigated. In
contrast to our findings, Sp1 has been shown to mediate HDAC
inhibitor (HDACi) induction of TRAIL expression. Mutation of
Sp1 binding sites blocked HDACi-induced TRAIL promoter
activity [25,50] and protein expression [50] in acute myeloid
leukemia and human breast cancer cells. However, knockdown of
Sp1 did not decrease basal TRAIL protein expression [50],
suggesting a differential regulation of basal and HDACi-induced
TRAIL expression in these cell lines.
In summary, our current study identifies the NFAT molecular
pathway as an important regulator of TRAIL. Furthermore, we
demonstrate that Sp1 inhibition increases TRAIL expression.
Importantly, the induction of TRAIL expression by NFATc1 is
not through the direct binding of NFATc1 to the TRAIL
promoter but through negative regulation of Sp1 binding. TRAIL
has been shown to play an important role in intestinal cell
differentiation [11]. Together with our previous findings showing
the importance of NFATc1 in the regulation of PTEN expres-
sion and intestinal cell differentiation [10], our current study
suggests that TRAIL, as a downstream target of NFAT signaling,
may be involved in NFAT-mediated regulation of intestinal cell
differentiation.
Materials and Methods
Materials
Phorbol 12-myristate 13-acetate (PMA) was purchased from
Sigma Chemical Company (St. Louis, MO). A23187 calcium
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ionophore (Io) was from Alexis Corporation (San Diego, CA).
The calcineurin inhibitor cyclosporine A (CsA) was from
Calbiochem (San Diego, CA). The plasmids encoding Flag-
tagged NFATc1, NFATc2, NFATc3 and empty vector (pDF30)
were kindly provided by Dr. Gerald R. Crabtree (Stanford
University, Stanford, CA). Mouse anti-TRAIL antibody used for
Western blot was purchased from IMGENEX Corporation (San
Diego, CA). Mouse antibodies against NFATc1, NFATc2 and
NFATc4 were from Affinity BioReagents, Inc. (Golden, CO).
Rabbit anti-b-actin antibody was from Sigma. Rabbit polyclonal
anti-Sp1 antibody (07-645) was from Upstate (Lake Placid, NY).
Mouse anti-NFATc3 antibody, the NFATc, NFATc mutant, Sp1,
and ETS oligonucleotides were from Santa Cruz Biotechnology
(Santa Cruz, CA). Human NFATc1, NFATc2, NFATc3,
NFATc4, Sp1, and control siRNA were purchased from
Dharmacon, Inc. (Lafayette, CO). [c-32P] ATP (3,000 Ci/mmol)
was from Amersham Pharmacia Biotech (Piscataway, NY).
Immobilon-P nylon membranes for Western blots were pur-
chased from Millipore (Bedford, MA), and x-ray film was
purchased from Eastman Kodak (Rochester, NY). Total RNA
was isolated using Ultraspec RNA from Biotecx Laboratories
(Houston, TX). The enhanced chemiluminescence (ECL) system
for Western immunoblot analysis was from Amersham (Arlington
Heights, IL). Tissue culture media was obtained from GIBCO-
BRL (Grand Island, NY). All other reagents were of molecular
biology grade and purchased from either Sigma or Amresco
(Solon, OH).
Cell culture and treatment
Human colon cancer cell lines HT29 and Caco-2 (obtained
from ATCC, Rockville, MD) were maintained in McCoy’s 5A
supplemented with 10% fetal calf serum (FCS) and MEM
supplemented with 15% of FCS, respectively. The cells were
pretreated with CsA for 30 min and then treated with PMA/Io in
the presence or absence of CsA.
Western blot analysis
Total protein was extracted and resolved on a 10% polyacryl-
amide gel and transferred to Immobilon-P nylon membranes as
we have described previously [51]. Filters were incubated for 1 h
at room temperature in blotting solution. TRAIL, Flag, Sp1, and
b-actin were detected with specific antibodies following blotting
with a horseradish peroxidase-conjugated secondary antibody and
visualized using an ECL detection system.
shRNAs and generation of stable cell lines
MISSION shRNA Lentiviral Particles with short-hairpin RNAs
(shRNAs) were purchased from Sigma. The control shRNA (Non-
Target shRNA Control Transduction Particles, catalog # SHC002V)
contains 4 base pair mismatches within the short hairpin sequence to
any known human or mouse genes. A set of four shRNAs to human
NFATc1 (NM_006162; Sigma) were used; the sequences were as
follows: CCGGCATCGAGATAACCTCGTGCTTCTCGAGAA-
GCACGAGGTTATCTCGATGTTTTT (TRCN0000017336), C-
CGGCGTCAGTTTCTACGTCTGCAACTCGAGTTGCAGA-
CGTAGAAACTGACGTTTTT (TRCN0000017335), CCGGCC-
CGCCAACGTTCCAATTATACTCGAGTATAATTGGAACG-
TTGGCGGGTTTTT (TRCN0000017334), CCGGCGGCAACA-
TTAGAAAGTGATTCTCGAGAATCACTTTCTAATGTTGC-
CGTTTTT (TRCN0000017333). HT29 cells were infected with the
control shRNA or shRNA to human NFATc1 lentivirus particles and
stably expressing cells were selected with puromycin at a concentration
of 2 mg/ml.
Preparation of nuclear extracts and electrophoretic
mobility shift assays (EMSAs)
The nuclear extracts were prepared using a kit according to the
manufacturer’s protocol. EMSAs were performed as described
previously [52] with minor modifications. Nuclear extracts (15 mg)
were incubated with 40,000 cpm of 32P-labeled consensus
oligonucleotide in a buffer containing 4% glycerol, 50 mM NaCl,
1 mM MgCl2, 0.5 mM dithiothreitol, 0.5 mM EDTA, 10 mM
Tris-HCl; pH 7.5) and 0.5 mg/ml poly(dI?dC) in a final volume of
20 ml, for 15 min at room temperature. For supershift studies, 2 ml
of antiserum was added to the nuclear protein for 20 min at room
temperature prior to the addition of labeled probe. The complexes
were fractionated on 6% native polyacrylamide gels run in 16
TBE buffer (89 mM Tris, 89 mM boric acid, and 2.0 mM
EDTA), dried, and exposed to Kodak X-AR film at 270uC.
Competition binding experiments were performed by the addition
of the nonradioactive oligonucleotide, in 100-fold molar excess, at
the time of addition of radioactive probe.
Chromatin immunoprecipitation (ChIP) assay
The ChIP assay was performed using the ChIP-IT Express
Enzymatic Kit (Active Motif) according to the manufacturer’s
protocol. PCR of the human TRAIL promoter containing the Sp1
binding sites was performed using total (input) or immunoprecip-
itated chromatin with the following pair of oligonucleotide
primers: 59- CATGGATCCTGAGGGCAAGG-39 and 59-TTG-
GCCCCACCCACATCTATTGAACC-39.
RNA isolation, real time PCR and reverse transcription-
PCR (RT-PCR)
Total RNA was isolated using the UltraspecTM RNA reagent.
Real-time RT-PCR was performed using Applied Biosystems
assays-on-demand 206assay mix of primers and Taq-Man MGB
probes (FAMTM dye-labeled) for target gene TRAIL (ID
Hs00234355_m1) and predeveloped 18S rRNA(VICTM dye-
labeled probe) TaqManH assay reagent (P/N 4319413E) for
endogenous control. Separate tubes (singleplex) one-step RT-
PCR was performed with 80 ng of RNA for both target gene and
endogenous control. The reagent was TaqMan one-step RT-
PCR master mix reagent kit (P/N 4309169). The cycling
parameters for one-step RT-PCR were: reverse transcription
48uC for 30 min, AmpliTaq activation 95uC for 10 min,
denaturation 95uC for 15 s, and annealing/extension 60uC for
1 min (repeat 40 times). Duplicate CT values were analyzed in
Microsoft Excel using the comparative CT(DDCT) method as
described by the manufacturer (Applied Biosystems). The amount
of target (22DDCT) was obtained by normalizing to the endo-
genous reference (18S) and relative to a calibrator (one of the
experimental samples).
RT-PCR was performed using a Titan One-Tube RT-PCR kit
(Roche Applied Science, Indianapolis, IN) according to the
manufacturer’s protocol. Cycling conditions were as follows:
95uC for 30 s, 54uC for 30 s, and 68uC for 50 s for 31 cycles.
Approximately 8 ml of product was run on a 0.56 Tris-borate-
EDTA-1% agarose gel. Primer sets were synthesized by Sigma as
follows: TRAIL (59-CTTCACAGTGCTCCTGCAGT-39 and 59-
TTAGCCAACTAAAAAGGCCCC-39), NFATc1 (59- GGAAG-
GGCGGCTTCTGCGAC-39 and 59- AGGCGTGCGGGCG-
CAGCAG-39), NFATc2 (59- CTGCCTCGCCACATCTACC-39
and 59-TGGTAGAAGGCGTGCGGCTT-39), NFATc3 (59-TG-
GATCTCAGTATCCTTTAA-39 and 59- TACACGAAACACA-
AGTCGTA-39), NFATc4 (59- TACAGATGTTCATCGGCAC-
39 and 59 CGAAGCTCAATGTCTGAAT-39).
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Human b-actin was amplified to assess loading using the PCR
primers supplied in the kit as follows: forward primer, 59-
CCAAGGCCAACCGCGAGAAGATGAC-39; reverse primer,
59-AGGGTACATGGTGGTGCCGCCAGAC.
Plasmids, siRNAs, transfections, and dual-luciferase assay
The NFATc1, NFATc2, NFATc3, NFATc4 and control siRNA
duplexes were introduced into HT29 cells by electroporation
(Gene Pulser, Bio-Rad) as we have described previously [53].
TRAIL promoter reporter constructs and plasmids overexpressing
NFATc1, NFATc2, NFATc3 and NFATc4 were transfected into
cells using Lipofectamine 2000. The pRL-Tk-luc plasmid was co-
transfected to normalize for variation in transfection efficiency.
Luciferase assays were performed as described previously [54].
Briefly, 48 h after transfection, the cells were rinsed with PBS,
harvested and lysed with 16 cell culture lysis reagent. Luciferase
activity in 20 ml of extract was assayed with the dual luciferase
assay system. Light emissions were integrated for the initial 10 s of
emission using a Monolight 2010 luminometer (Analytical
Luminescence Laboratory).
Statistical analysis
Due to the heterogeneous variability among groups, data in
Figure 3D and Figure 4D was analyzed using the Kruskal-Wallis
test using SASH, Release 9.1. Data presented in Figure 1A, 2B, 3F,
5E was analyzed using t test. Group differences were assessed at
the 0.05 level of significance.
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